Home › Targets › PD-L1

PD-L1 (10 companies · 16 programs)

Companies with an active program directed at PD-L1.

Compass Therapeutics, Inc. CMPX

CTX-8371 — Non-Small Cell Lung Cancer Phase 1
CTX-8371 — Triple-Negative Breast Cancer Phase 1
CTX-8371 — Hodgkin Lymphoma Phase 1

ImmunityBio, Inc. IBRX

PD-L1 t-haNK — Triple-Negative Breast Cancer Phase 1
PD-L1 t-haNK — Pancreatic Cancer Phase 2
PD-L1 t-haNK — Glioblastoma Phase 1

KAZIA THERAPEUTICS LTD KZIA

NDL2 — Breast Cancer Preclinical
NDL2 — Non-Small Cell Lung Cancer Preclinical
NDL2 Preclinical

Adagene Inc. ADAG

ADG104 Phase 2

Aptevo Therapeutics Inc. APVO

APVO711 Preclinical

BriaCell Therapeutics Corp. BCTX

Soluble CD80 Preclinical

CRESCENT BIOPHARMA, INC. CBIO

CR-002 Preclinical

EXELIXIS, INC. EXEL

XB628 — Solid Tumors Phase 1

Fortress Biotech, Inc. FBIO

UNLOXCYT — Cutaneous Squamous Cell Carcinoma Approved

NovaBridge Biosciences NBP

ragistomig — Solid Tumors Phase 1